T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) Files An 8-K Results of Operations and Financial Condition
Item 2.02
T2 Biosystems, Inc. Exhibit
EX-99.1 2 d903601dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 T2 Biosystems Announces Preliminary First Quarter 2020 Financial Results Suspends 2020 Financial Guidance LEXINGTON,…
To view the full exhibit click here
About T2 BIOSYSTEMS, INC. (NASDAQ:TTOO)
T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.
